Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy

• Published in: Supportive care in cancer Vol. 27; no. 5; pp. 1845 - 1852
• Main Authors: Levy, David, Dhillon, Haryana M., Lomax, Anna, Marthick, Michael, McNeil, Catriona, Kao, Steven, Lacey, Judith
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2019; Springer; Springer Nature B.V
• Subjects: Adult; Aged; Analysis; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents, Immunological - therapeutic use; Cancer; Care and treatment; Decision Making; Drug therapy; Feasibility Studies; Female; Humans; Immunotherapy; Immunotherapy - methods; Immunotherapy - psychology; Male; Medicine; Medicine & Public Health; Melanoma; Melanoma - drug therapy; Melanoma - pathology; Melanoma - psychology; Metastasis; Middle Aged; Monoclonal antibodies; Neoplasm Metastasis; Nursing; Nursing Research; Oncology; Original Article; Pain Medicine; Qualitative Research; Rehabilitation Medicine; Targeted cancer therapy; Uncertainty; Qualitative research; Metastatic melanoma; Uncertainty; Immune checkpoint inhibitor; Feasibility study; Immunotherapy; Supportive care; Cancer
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-018-4443-3

Objective Little is known about the lived experiences of patients with metastatic melanoma undergoing checkpoint inhibitor treatment. We conducted a feasibility study of a supportive care intervention for melanoma patients being treated with pembrolizumab. Here, we report a secondary objective of the study, which was to explore the lived experience of being on pembrolizumab treatment for advanced melanoma. Methods Twenty-eight participants with metastatic melanoma were recruited across two cohorts, all receiving 3-weekly immunotherapy treatment. Semi-structured interviews were conducted with 26 participants once at 9 weeks. Thematic analysis using interpretative phenomenological analysis (IPA) was performed with multiple iterations of data review to achieve consensus. Results Three overarching themes were identified; here, we report the first and most dominant theme: how metastatic melanoma patients live within uncertain spaces. Although immunotherapy increases overall survival, metastatic melanoma patients live within an uncertain spectrum. They confront uncertainty related to immunotherapy treatment, their disease trajectory, family relationships, and decision-making. Melanoma patients attempt to normalize their lives, engaging in their usual activities. Uncertainty increases prior to active treatment and intensifies during investigation phases. Conclusions Despite progress in melanoma patient treatment and outcomes, these patients face sustained uncertainty about their disease trajectory.